Pradžia › Difuzinė sklerodermija › Ilinoisas
Difuzinė sklerodermija klinikiniai tyrimai Ilinoisas
8 tyrimai dėl Difuzinė sklerodermija ieško dalyvių vietose Ilinoisas.
Miestai Ilinoisas
Oficialus tyrimo tekstas (anglų kalba)
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- University of Chicago Hospitals, Chicago
Renkami dalyviai2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-28 · NCT06470048A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Renkami dalyviai1 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-09-10 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-08-28 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Renkami dalyviai2/3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-17 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-07 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-31 · NCT06991114Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.